The invention provides a pharmaceutical composite for treating cerebral stroke, which is prepared from the following ingredients in portion by weight: 1-50 portions of astragalosides, 1-50 portions of salvia miltiorrhiza extract and 0.5-30 portions of ligusticum chuanxiong oil. The invention further provides a medicine prepared from the active pharmaceutical ingredients of astragalosides, salvia miltiorrhiza extract and ligusticum chuanxiong oil. The medicine, due to the adoption of middle cerebral artery occlusion model (MCAO model) and the application of modern histopathology, flow cytometry and molecular biotechnology, has the effect of reducing cerebral infarction volume, protecting nerve cell, inhibiting apoptosis after cerebral ischaemia and blocking inflammatory reaction in ischemic infarction area. Through experiment, the result shows that, due to the compatibility of three ingredients, the medicine has the advantages of obvious synergism, definite efficacy and controllable quality, thereby clinically providing a new medicine for treating cerebral stroke.